Literature DB >> 14564189

Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients.

Mevlut Baskol1, Sebnem Gursoy, Gulden Baskol, Omer Ozbakir, Kadri Guven, Mehmet Yucesoy.   

Abstract

The goal of this study is to establish whether 5 days of ceftriaxone treatment was sufficient to cure culture-negative neutrocytic ascites in cirrhotic patients. We studied 50 cirrhotic patients with culture-negative neutrocytic ascites. All were treated with ceftriaxone, 1.0 g IV, twice a day for 5 days. A control paracentesis was performed 48 hours after starting the therapy to assess response to the treatment. A total of 17 demographic, clinical, and laboratory variables were recorded in all cases on the day of diagnosis of CNNA. The mean age of the patients was 57.7 +/- 13.2 years. Thirty-two patients were males and 18 females. The etiology of cirrhosis was hepatitis C virus in 20 patients (40%), hepatitis B virus in 16 patients (32%), cryptogenic in 13 patients (26%), and alcohol abuse in 1 patient (2%). Eighty percent of the patients were in Child-Pugh Class C. Resolution rate of culture-negative neutrocytic ascites on day 5 of treatment was 78%. Hospital mortality in cirrhotic patients with culture negative neutrocytic ascites was 4%. Statistical analysis showed that none of the 13 selected variables as covariates significantly related with the resolution of culture-negative neutrocytic ascites. Five days of ceftriaxone treatment is an adequate therapy for culture-negative neutrocytic ascites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564189     DOI: 10.1097/00004836-200311000-00011

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis.

Authors:  Eric Ardolino; Susan S Wang; Vilas R Patwardhan
Journal:  Dig Dis Sci       Date:  2019-02-14       Impact factor: 3.199

2.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 3.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

Review 4.  Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies.

Authors:  Sebastián Marciano; Juan Manuel Díaz; Melisa Dirchwolf; Adrián Gadano
Journal:  Hepat Med       Date:  2019-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.